450 related articles for article (PubMed ID: 25458869)
1. Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP.
Andoh T; Kuraishi Y
J Dermatol Sci; 2014 Dec; 76(3):206-13. PubMed ID: 25458869
[TBL] [Abstract][Full Text] [Related]
2. Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis.
Andoh T; Yoshida T; Kuraishi Y
Exp Dermatol; 2014 May; 23(5):359-61. PubMed ID: 24645735
[TBL] [Abstract][Full Text] [Related]
3. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model.
Ishii N; Shirato M; Wakita H; Miyazaki K; Takase Y; Asano O; Kusano K; Yamamoto E; Inoue C; Hishinuma I
J Pharmacol Exp Ther; 2013 Jul; 346(1):105-12. PubMed ID: 23674603
[TBL] [Abstract][Full Text] [Related]
4. A putative antipruritic mechanism of the phosphodiesterase-4 inhibitor E6005 by attenuating capsaicin-induced depolarization of C-fibre nerves.
Wakita H; Ohkuro M; Ishii N; Hishinuma I; Shirato M
Exp Dermatol; 2015 Mar; 24(3):215-6. PubMed ID: 25431172
[TBL] [Abstract][Full Text] [Related]
5. Involvement of leukotriene B4 in dermatophyte-related itch in mice.
Andoh T; Takayama Y; Kuraishi Y
Pharmacol Rep; 2014 Aug; 66(4):699-703. PubMed ID: 24948074
[TBL] [Abstract][Full Text] [Related]
6. Induction of leukotriene B(4) and prostaglandin E(2) release from keratinocytes by protease-activated receptor-2-activating peptide in ICR mice.
Zhu Y; Wang XR; Peng C; Xu JG; Liu YX; Wu L; Zhu QG; Liu JY; Li FQ; Pan YH; You BM; Hu JH
Int Immunopharmacol; 2009 Oct; 9(11):1332-6. PubMed ID: 19712758
[TBL] [Abstract][Full Text] [Related]
7. Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis.
Furue M; Kadono T; Tsuji G; Nakahara T
Expert Opin Investig Drugs; 2017 Dec; 26(12):1403-1408. PubMed ID: 29068253
[TBL] [Abstract][Full Text] [Related]
8. Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle-controlled exploratory trial.
Nemoto O; Hayashi N; Kitahara Y; Furue M; Hojo S; Nomoto M; Shima S;
J Dermatol; 2016 Aug; 43(8):881-7. PubMed ID: 26703371
[TBL] [Abstract][Full Text] [Related]
9. Glycyrrhetinic acid prevents cutaneous scratching behavior in mice elicited by substance P or PAR-2 agonist.
Akasaka Y; Yoshida T; Tsukahara M; Hatta A; Inoue H
Eur J Pharmacol; 2011 Nov; 670(1):175-9. PubMed ID: 21925497
[TBL] [Abstract][Full Text] [Related]
10. Effect of the phosphodiesterase 4 inhibitor E6005 on nerve growth factor elevation in irritated skin of NC/Nga mice.
Ishii N; Wakita H; Shirato M
J Dermatol Sci; 2014 Dec; 76(3):263-4. PubMed ID: 25455141
[No Abstract] [Full Text] [Related]
11. An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice.
Kubota S; Watanabe M; Shirato M; Okuno T; Higashimoto I; Machida K; Yokomizo T; Inoue H
Eur J Pharmacol; 2015 Dec; 768():41-8. PubMed ID: 26455478
[TBL] [Abstract][Full Text] [Related]
12. Thromboxane A2 is Involved in Itch-associated Responses in Mice with Atopic Dermatitis-like Skin Lesions.
Andoh T; Yamamoto A; Haza S; Yuhki KI; Ushikubi F; Narumiya S; Kuraishi Y
Acta Derm Venereol; 2016 Nov; 96(7):899-904. PubMed ID: 27066774
[TBL] [Abstract][Full Text] [Related]
13. Methods for preclinical assessment of antipruritic agents and itch mechanisms independent of mast-cell histamine.
Kuraishi Y
Biol Pharm Bull; 2015; 38(5):635-44. PubMed ID: 25947907
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study.
Ohba F; Matsuki S; Imayama S; Matsuguma K; Hojo S; Nomoto M; Akama H
J Dermatolog Treat; 2016 Oct; 27(5):467-72. PubMed ID: 27080209
[TBL] [Abstract][Full Text] [Related]
15. Scratching behavior in mice induced by the proteinase-activated receptor-2 agonist, SLIGRL-NH2.
Shimada SG; Shimada KA; Collins JG
Eur J Pharmacol; 2006 Jan; 530(3):281-3. PubMed ID: 16356490
[TBL] [Abstract][Full Text] [Related]
16. Participation of proteinase-activated receptor-2 in passive cutaneous anaphylaxis-induced scratching behavior and the inhibitory effect of tacrolimus.
Zhu Y; Peng C; Xu JG; Liu YX; Zhu QG; Liu JY; Li FQ; Wu JH; Hu JH
Biol Pharm Bull; 2009 Jul; 32(7):1173-6. PubMed ID: 19571380
[TBL] [Abstract][Full Text] [Related]
17. Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice.
Ui H; Andoh T; Lee JB; Nojima H; Kuraishi Y
Eur J Pharmacol; 2006 Jan; 530(1-2):172-8. PubMed ID: 16359660
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial.
Furue M; Kitahara Y; Akama H; Hojo S; Hayashi N; Nakagawa H;
J Dermatol; 2014 Jul; 41(7):577-85. PubMed ID: 24942594
[TBL] [Abstract][Full Text] [Related]
19. Hydrogen sulfide donors alleviate itch secondary to the activation of type-2 protease activated receptors (PAR-2) in mice.
Coavoy-Sánchez SA; Rodrigues L; Teixeira SA; Soares AG; Torregrossa R; Wood ME; Whiteman M; Costa SKP; Muscará MN
Pharmacol Res; 2016 Nov; 113(Pt A):686-694. PubMed ID: 27720932
[TBL] [Abstract][Full Text] [Related]
20. Leukotriene B(4) mediates sphingosylphosphorylcholine-induced itch-associated responses in mouse skin.
Andoh T; Saito A; Kuraishi Y
J Invest Dermatol; 2009 Dec; 129(12):2854-60. PubMed ID: 19657356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
